U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-512669-15-00

Enrollment

Registered

2024-03-20

Start date

2022-03-24

Completion date

2025-01-22

Last updated

2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic arthritis

Brief summary

BOLD signal voxel count at week 1 and week 12 compared to baseline

Interventions

DRUGRINVOQ 15 mg prolonged-release tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
BOLD signal voxel count at week 1 and week 12 compared to baseline	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026